Nov 6, 2019
|
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
|
Oct 10, 2019
|
Ardelyx to Host Analyst Day in New York
|
Sep 17, 2019
|
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
|
Sep 12, 2019
|
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
|
Sep 3, 2019
|
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
|
Sep 2, 2019
|
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
|
Aug 9, 2019
|
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
|
May 30, 2019
|
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
|
May 7, 2019
|
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
|
Mar 14, 2019
|
Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
|